TEVA PHARMACEUTICAL-SP ADR (TEVA) Stock News

USA - NYSE:TEVA - US8816242098 - ADR

19.735 USD

+0.13 (+0.64%)

Last: 10/28/2025, 3:18:00 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

TEVA Latest News, Press Relases and Analysis

All

Press Releases

7 days ago - By: Teva Pharmaceutical Industries Ltd

Teva und Prestige Biopharma schließen Lizenzvereinbarung für die Vermarktung von Tuznue® in Europa

7 days ago - By: Teva Pharmaceutical Industries Ltd

Teva et Prestige Biopharma concluent un accord de licence pour la commercialisation de Tuznue® en Europe

8 days ago - By: Teva Pharmaceutical Industries Ltd

Teva and Prestige Biopharma Enter License Agreement for Tuznue® Commercialization in Europe

8 days ago - By: Teva Pharmaceutical Industries Ltd

Teva and Prestige Biopharma Enter License Agreement for Tuznue® Commercialization in Europe

13 days ago - By: Benzinga - Mentions: XBI IBB JAZZ SPRC ...

SciSparc Expands Biotech Ambitions, Buys Stake In Miza III Ventures

a month ago - By: Benzinga

Is Teva Pharmaceutical Indus Gaining or Losing Market Support?

2 months ago - By: Stocktwits - Mentions: IYLD DFAX

News Image

This Pharma Stock Is Down 19% In 2025 But Just Received An ‘Explosive News’ – Find Out More

15 days ago - By: Zacks Investment Research - Mentions: SNY ALLO CMMB

TEVA Gets FDA Nod for Uzedy Label Expansion in Bipolar I Disorder

15 days ago - By: The Motley Fool - Mentions: NVDA PLTR

Billionaire Stanley Druckenmiller Is Selling Nvidia and Palantir and Piling Into One of Wall Street's Hottest Drug Stocks Ahead of 2026

18 days ago - By: Teva Pharmaceutical Industries Ltd

FDA Approves Expanded Indication for UZEDY® (risperidone) Extended-Release Injectable Suspension as a Treatment for Adults Living with Bipolar I Disorder

18 days ago - By: Teva Pharmaceutical Industries Ltd

FDA Approves Expanded Indication for UZEDY® (risperidone) Extended-Release Injectable Suspension as a Treatment for Adults Living with Bipolar I Disorder

18 days ago - By: Zacks Investment Research - Mentions: JNJ AMGN KVUE

Buying J&J Stock Ahead of Q3 Earnings? Here's What You Should Know

23 days ago - By: The Motley Fool - Mentions: PLTR NVDA TSM

Billionaire Stanley Druckenmiller Sold His Fund's Stakes in Nvidia and Palantir, and Has Piled Into These 2 Phenomenal Stocks for 4 Straight Quarters

a month ago - By: Zacks Investment Research - Mentions: SNY FOLD

Can Galafold Drive Amicus' Growth Through the Rest of 2025?

a month ago - By: Zacks Investment Research

Why Teva Pharmaceutical Industries Ltd. (TEVA) is a Top Value Stock for the Long-Term

a month ago - By: Zacks Investment Research - Mentions: RDY ALVO

Here's How Alvotech is Expanding its Portfolio Beyond Immunology

a month ago - By: Teva Pharmaceutical Industries Ltd

Teva to Host Conference Call to Discuss Third Quarter 2025 Financial Results at 8 a.m. ET on November 5, 2025

a month ago - By: Teva Pharmaceutical Industries Ltd

Teva Releases Q3 2025 Aide Memoire

a month ago - By: Teva Pharmaceutical Industries Ltd

Teva Releases Q3 2025 Aide Memoire

a month ago - By: Teva Pharmaceutical Industries Ltd

Teva to Host Conference Call to Discuss Third Quarter 2025 Financial Results at 8 a.m. ET on November 5, 2025

a month ago - By: Teva Pharmaceutical Industries Ltd

Patients Taking AUSTEDO XR® (deutetrabenazine) extended-release tablets Reported Symptom Improvement and High Satisfaction

a month ago - By: Teva Pharmaceutical Industries Ltd

Patients Taking AUSTEDO XR® (deutetrabenazine) extended-release tablets Reported Symptom Improvement and High Satisfaction

a month ago - By: Teva Pharmaceutical Industries Ltd

New Long-term Safety Data from the Completed Phase 3 SOLARIS Trial Support the Potential of Olanzapine LAI (TEV-'749) as the First Long-Acting Olanzapine Treatment Option for Schizophrenia with No PDSS Observed

a month ago - By: Teva Pharmaceutical Industries Ltd

New Long-term Safety Data from the Completed Phase 3 SOLARIS Trial Support the Potential of Olanzapine LAI (TEV-'749) as the First Long-Acting Olanzapine Treatment Option for Schizophrenia with No PDSS Observed

a month ago - By: Teva Pharmaceutical Industries Ltd

Teva to Host Conference Call to Discuss Data from the Completed Phase 3 SOLARIS Trial For Olanzapine LAI (TEV-‘749) on September 22, 2025 After Presentations at the Psych Congress Annual meeting

a month ago - By: Teva Pharmaceutical Industries Ltd

Teva to Host Conference Call to Discuss Data from the Completed Phase 3 SOLARIS Trial For Olanzapine LAI (TEV-‘749) on September 22, 2025 After Presentations at the Psych Congress Annual meeting

a month ago - By: Yahoo Finance

Teva Pharmaceutical Industries Limited (TEVA)’s Emrusolmin Gains FDA Fast Track for Multiple System Atrophy

2 months ago - By: Zacks Investment Research - Mentions: RDY ALVO

ALVO Stock Trades Near 52-Week Low: Should You Buy, Hold or Sell?

2 months ago - By: Teva Pharmaceutical Industries Ltd

Teva’s Emrusolmin Granted U.S. FDA Fast Track Designation for Treatment of Multiple System Atrophy

2 months ago - By: Zacks Investment Research - Mentions: SNY BMY NVO

TEVA Stock Up More Than 19% in a Month: Buy, Sell or Hold the Stock?

2 months ago - By: Teva Pharmaceutical Industries Ltd

Teva to Present at Morgan Stanley Global Healthcare Conference and Bank of America Global Healthcare Conference in September

2 months ago - By: Teva Pharmaceutical Industries Ltd

Teva to Present at Morgan Stanley Global Healthcare Conference and Bank of America Global Healthcare Conference in September

2 months ago - By: Yahoo Finance

Teva Pharmaceutical Industries Limited (TEVA) Gains FDA Nod for Pediatric Migraine Drug AJOVY

2 months ago - By: Investor's Business Daily - Mentions: NVO

FDA Approves First-Ever Generic Weight-Loss Drug In A Blow To Novo Nordisk

2 months ago - By: Teva Pharmaceutical Industries Ltd

Teva Announces FDA Approval and Launch of Generic Saxenda® (liraglutide injection) – First Generic GLP-1 Indicated for Weight Loss